Masimo Corp (MASI)

$101.41

+0.04

(+0.04%)▲

Market is closed - opens 8 PM, 06 Dec 2023

Performance

  • $99.39
    $102.14
    $101.41
    downward going graph

    1.99%

    Downside

    Day's Volatility :2.69%

    Upside

    0.71%

    downward going graph
  • $75.22
    $198.00
    $101.41
    downward going graph

    25.83%

    Downside

    52 Weeks Volatility :62.01%

    Upside

    48.78%

    downward going graph

Returns

PeriodMasimo Corp
3 Months
-8.11%
6 Months
-38.98%
1 Year
-26.86%
3 Years
-62.09%

Highlights

Market Capitalization
5.1B
Book Value
$24.14
Dividend Share
0.0
Dividend Yield
1.55%
Earnings Per Share (EPS)
1.63
PE Ratio
59.33
PEG Ratio
4.73
Wall Street Target Price
92.0
Profit Margin
4.18%
Operating Margin TTM
5.68%
Return On Assets TTM
3.36%
Return On Equity TTM
7.0%
Revenue TTM
2.1B
Revenue Per Share TTM
40.16
Quarterly Revenue Growth YOY
-12.8%
Gross Profit TTM
1.1B
EBITDA
302.3M
Diluted Eps TTM
1.63
Quarterly Earnings Growth YOY
-0.71
EPS Estimate Current Year
2.91
EPS Estimate Next Year
3.08
EPS Estimate Current Quarter
0.59
EPS Estimate Next Quarter
1.34

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Masimo Corp(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 9.28%

Current $101.41
Target $92.00

Company Financials

FY17Y/Y Change
Revenue
798.1M
↑ 14.9%
Net Income
131.6M
↓ 56.23%
Net Profit Margin
16.49%
↓ 26.79%
FY18Y/Y Change
Revenue
858.3M
↑ 7.54%
Net Income
193.5M
↑ 47.05%
Net Profit Margin
22.55%
↑ 6.06%
FY19Y/Y Change
Revenue
937.8M
↑ 9.27%
Net Income
196.2M
↑ 1.38%
Net Profit Margin
20.92%
↓ 1.63%
FY20Y/Y Change
Revenue
1.1B
↑ 21.96%
Net Income
240.3M
↑ 22.47%
Net Profit Margin
21.01%
↑ 0.09%
FY21Y/Y Change
Revenue
1.2B
↑ 8.34%
Net Income
229.6M
↓ 4.43%
Net Profit Margin
18.53%
↓ 2.48%
FY22Y/Y Change
Revenue
2.0B
↑ 64.29%
Net Income
143.5M
↓ 37.51%
Net Profit Margin
7.05%
↓ 11.48%
Q2 FY22Q/Q Change
Revenue
565.3M
↑ 85.81%
Net Income
18.1M
↓ 61.15%
Net Profit Margin
3.2%
↓ 12.12%
Q3 FY22Q/Q Change
Revenue
549.3M
↓ 2.83%
Net Income
37.9M
↑ 109.39%
Net Profit Margin
6.9%
↑ 3.7%
Q4 FY22Q/Q Change
Revenue
617.0M
↑ 12.32%
Net Income
40.9M
↑ 7.92%
Net Profit Margin
6.63%
↓ 0.27%
Q1 FY23Q/Q Change
Revenue
565.0M
↓ 8.43%
Net Income
21.3M
↓ 47.92%
Net Profit Margin
3.77%
↓ 2.86%
Q2 FY23Q/Q Change
Revenue
455.3M
↓ 19.42%
Net Income
15.7M
↓ 26.29%
Net Profit Margin
3.45%
↓ 0.32%
Q3 FY23Q/Q Change
Revenue
478.9M
↑ 5.18%
Net Income
10.6M
↓ 32.48%
Net Profit Margin
2.21%
↓ 1.24%
FY17Y/Y Change
Total Assets
910.2M
↑ 10.93%
Total Liabilities
203.3M
↓ 21.89%
FY18Y/Y Change
Total Assets
1.2B
↑ 26.87%
Total Liabilities
185.8M
↓ 8.64%
FY19Y/Y Change
Total Assets
1.4B
↑ 20.9%
Total Liabilities
228.3M
↑ 22.88%
FY20Y/Y Change
Total Assets
1.7B
↑ 22.66%
Total Liabilities
304.9M
↑ 33.58%
FY21Y/Y Change
Total Assets
1.9B
↑ 10.19%
Total Liabilities
336.8M
↑ 10.45%
FY22Y/Y Change
Total Assets
3.2B
↑ 70.14%
Total Liabilities
1.9B
↑ 455.79%
Q2 FY22Q/Q Change
Total Assets
3.0B
↑ 55.13%
Total Liabilities
1.8B
↑ 438.3%
Q3 FY22Q/Q Change
Total Assets
3.1B
↑ 3.22%
Total Liabilities
1.8B
↑ 2.58%
Q4 FY22Q/Q Change
Total Assets
3.2B
↑ 5.05%
Total Liabilities
1.9B
↑ 3.76%
Q1 FY23Q/Q Change
Total Assets
3.1B
↓ 2.96%
Total Liabilities
1.8B
↓ 4.62%
Q2 FY23Q/Q Change
Total Assets
3.0B
↓ 3.35%
Total Liabilities
1.7B
↓ 4.61%
Q3 FY23Q/Q Change
Total Assets
3.0B
↓ 0.51%
Total Liabilities
1.7B
↑ 1.02%
FY17Y/Y Change
Operating Cash Flow
58.1M
↓ 86.06%
Investing Cash Flow
-47.9M
↑ 89.25%
Financing Cash Flow
-4.1M
↓ 98.09%
FY18Y/Y Change
Operating Cash Flow
239.5M
↑ 312.21%
Investing Cash Flow
-26.2M
↓ 45.41%
Financing Cash Flow
25.8M
↓ 723.01%
FY19Y/Y Change
Operating Cash Flow
221.6M
↓ 7.47%
Investing Cash Flow
-197.7M
↑ 655.89%
Financing Cash Flow
-9.3M
↓ 136.23%
FY20Y/Y Change
Operating Cash Flow
211.0M
↓ 4.82%
Investing Cash Flow
-82.8M
↓ 58.12%
Financing Cash Flow
-54.3M
↑ 481.51%
FY21Y/Y Change
Operating Cash Flow
264.8M
↑ 25.5%
Investing Cash Flow
-37.5M
↓ 54.67%
Financing Cash Flow
-122.4M
↑ 125.39%
FY22Y/Y Change
Operating Cash Flow
29.5M
↓ 88.86%
Investing Cash Flow
-1.1B
↑ 2718.35%
Financing Cash Flow
520.3M
↓ 525.07%
Q2 FY22Q/Q Change
Operating Cash Flow
2.4M
↓ 89.46%
Investing Cash Flow
-1.0B
↑ 4117.96%
Financing Cash Flow
518.2M
↓ 2431.92%
Q3 FY22Q/Q Change
Operating Cash Flow
10.4M
↑ 325.88%
Investing Cash Flow
-7.7M
↓ 99.23%
Financing Cash Flow
29.1M
↓ 94.38%
Q4 FY22Q/Q Change
Operating Cash Flow
-6.6M
↓ 163.46%
Investing Cash Flow
-22.8M
↑ 196.1%
Financing Cash Flow
-4.7M
↓ 116.15%
Q1 FY23Q/Q Change
Operating Cash Flow
400.0K
↓ 106.06%
Investing Cash Flow
-11.1M
↓ 51.32%
Financing Cash Flow
-35.2M
↑ 648.94%
Q2 FY23Q/Q Change
Operating Cash Flow
23.6M
↑ 5800.0%
Investing Cash Flow
-22.4M
↑ 101.8%
Financing Cash Flow
-4.9M
↓ 86.08%

Technicals Summary

Sell

Neutral

Buy

Masimo Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Masimo Corp
Masimo Corp
24.32%
-38.98%
-26.86%
-62.09%
-6.14%
Stryker Corporation
Stryker Corporation
4.94%
5.05%
23.34%
22.68%
68.47%
Dexcom, Inc.
Dexcom, Inc.
23.58%
-6.52%
0.32%
38.94%
262.09%
Boston Scientific Corp.
Boston Scientific Corp.
3.92%
8.31%
21.52%
60.23%
49.25%
Abbott Laboratories
Abbott Laboratories
9.84%
1.69%
0.47%
-2.64%
45.86%
Medtronic Plc
Medtronic Plc
7.35%
-5.72%
2.26%
-30.01%
-18.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Masimo Corp
Masimo Corp
59.33
59.33
4.73
2.91
0.07
0.03
0.02
24.14
Stryker Corporation
Stryker Corporation
44.25
44.25
2.89
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
128.52
128.52
2.39
1.43
0.18
0.06
0.0
5.87
Boston Scientific Corp.
Boston Scientific Corp.
68.46
68.46
1.75
2.01
0.07
0.04
0.02
12.89
Abbott Laboratories
Abbott Laboratories
35.67
35.67
25.14
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.97
25.97
1.61
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Masimo Corp
Masimo Corp
Buy
$5.1B
-6.14%
59.33
4.18%
Stryker Corporation
Stryker Corporation
Buy
$113.1B
68.47%
44.25
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$45.1B
262.09%
128.52
11.08%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$82.2B
49.25%
68.46
8.93%
Abbott Laboratories
Abbott Laboratories
Buy
$182.1B
45.86%
35.67
12.92%
Medtronic Plc
Medtronic Plc
Buy
$106.4B
-18.1%
25.97
12.84%

Institutional Holdings

  • BlackRock Inc

    10.24%

  • FMR Inc

    9.93%

  • Vanguard Group Inc

    9.00%

  • Politan Capital Management LP

    8.92%

  • Capital Research Global Investors

    4.04%

  • Massachusetts Financial Services Company

    2.86%

Company Information

masimo (nasdaq: masi) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. our work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life for more than 27 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. the result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making. masimo is for‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see. we're looking for people who can, do, and will make a difference. we think you'll like what you see.

Organization
Masimo Corp
Employees
4000
CEO
Mr. Joseph E. Kiani
Industry
Health Technology

Discover More

FAQs